NCT02381470 is a Phase 2 clinical trial of Faropenem in Pulmonary Tuberculosis, sponsored by National University Hospital, Singapore.

Who is sponsoring NCT02381470?

NCT02381470 is sponsored by National University Hospital, Singapore.

What drugs are being tested in NCT02381470?

Interventions in NCT02381470: Faropenem, Amoxicillin/clavulanic acid, Cefadroxil, Rifampicin.

What condition does NCT02381470 study?

NCT02381470 studies Pulmonary Tuberculosis.

Is NCT02381470 still recruiting?

NCT02381470 is currently completed. Last updated 23 March 2020.

Last reviewed 2020-03-23 · How we verify

NCT02381470

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers

Completed Phase 2 Last updated 23 March 2020

What this trial tests

Phase 2 trial testing Faropenem in Pulmonary Tuberculosis in 58 participants. Completed in 2 October 2019.

Timeline

11 February 2019

Primary endpoint
28 September 2019

2 October 2019

Quick facts

Lead sponsor	National University Hospital, Singapore
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	58
Start date	11 February 2019
Primary completion	28 September 2019
Estimated completion	2 October 2019
Sites	6 locations across Philippines, Singapore, Uganda

Drugs / interventions tested

Faropenem (FAROPENEM) — full drug profile →
Amoxicillin/clavulanic acid
Cefadroxil (CEFADROXIL) — full drug profile →
Rifampicin (Rifampicin) — full drug profile →

Conditions studied

Pulmonary Tuberculosis — all drugs for Pulmonary Tuberculosis →

Sponsor

National University Hospital, Singapore

Who can join

Adults 18 to 70, any sex, with Pulmonary Tuberculosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial aims to determine whether the early bactericidal activity of rifampicin given with faropenem or cefadroxil (each given with amoxicillin/clavulanic acid) is greater than the activity of rifampicin alone in patients with pulmonary TB. The trial will also investigate potential new biomarkers of sterilising activity.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Sotgiu G, D'Ambrosio L, Centis R, Tiberi S, et al · · 2016 · cited 64× · PMID 26985890 · DOI 10.3390/ijms17030373
Have we realized the full potential of β-lactams for treating drug-resistant TB?
Story-Roller E, Lamichhane G. · · 2018 · cited 35× · PMID 29934998 · DOI 10.1002/iub.1875
Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and intracellular killing of <i>Mycobacterium tuberculosis</i>.
Olivença F, Pires D, Silveiro C, Gama B, et al · · 2024 · cited 8× · PMID 38411952 · DOI 10.1128/aac.01586-23
Identification of drivers of mycobacterial resistance to peptidoglycan synthesis inhibitors.
Olivença F, Ferreira C, Nunes A, Silveiro C, et al · · 2022 · cited 7× · PMID 36147841 · DOI 10.3389/fmicb.2022.985871
Current and emerging therapies for pulmonary tuberculosis in adults.
Mahmood A, Ashfaq MB, Drain C, Melby E, et al · · 2026 · PMID 42046646 · DOI 10.1136/bmjmed-2025-001836

Verify or expand the search:

Other trials of Faropenem

Trials testing the same drug.

NCT06804096 — Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP) · Phase 4 · recruiting

Other recruiting trials for Pulmonary Tuberculosis

Currently open trials in the same condition.

NCT07209761 — A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis · Phase 3 · recruiting
NCT06192160 — Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis · Phase 2 · recruiting
NCT07186478 — I-FALMIN Albumin Supplement for Patients With Pulmonary Tuberculosis · NA · active not recruiting
NCT06649721 — Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort · Phase 3 · active not recruiting
NCT06528418 — Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath · recruiting

Other National University Hospital, Singapore trials

Trials by the same sponsor.

NCT06027983 — Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors · Phase 1, PHASE2 · not yet recruiting
NCT07460505 — Mandibular Advancement to Reduce Ventricular Load and Improve Quality-of-life in Heart Failure · NA · not yet recruiting
NCT07319676 — Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas · Phase 1, PHASE2 · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07091175 — Dupilumab Therapy in Nephrotic Syndrome in Children · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02381470 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National University Hospital, Singapore
Last refreshed: 23 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02381470.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing